Maegim

Stock search

Search by company name, 6-digit code, or Korean initials (e.g. ㅅㅅㅈㅈ)

한국어

ORGANOIDSCIENCES LTD.

오가노이드사이언스476040KOSDAQSector: Pharma & Biotech
₩6,9200.86%Market cap ₩45.6BAs of Sep 1, 2026 close · updated once daily
Market cap
₩45.6B
#1189 in KOSDAQ
Loss
PER not computable
1.85x
Sector median 1.61x
0.0%
Sector median 0.0%
D
Grade D31.3 ptsBottom 17% of 2,523 graded stocksMethodology v2.0

As of Sep 1, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

How to read this grade
SABCDCurrentF

Toward S means a higher total-score band; toward F, a lower band. Badges are distinguished by ink intensity and shape (fill, outline, dashed) — never by hue.

Maegim maps a total score — built from sector-relative percentile scoring — onto fixed, predefined thresholds to assign one of six bands, S to F. This stock is scored by the same formula as all 2,523 graded stocks and is currently in band D with a total score of 31.3 points.

Growth momentum not rated — will be included automatically as data accumulates

Position within sector

Mechanically selected indicators in the top or bottom 30% of sector percentiles · among 250 stocks in Pharma & Biotech

1-year closing price

Loading closing price history…
 
Low ₩6,600High ₩44,600
Latest close
Price change by period
1W
1.10%
1M
6.80%
3M
50.60%
1Y
77.40%

As of the Sep 1, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

1

Financial strength

34.1/100
How much debt does it carry relative to equity?
49.7%
Sector median 51.6%
Sector lowhighTop 47.6% in sector
Can it cover what's due within a year?
265.5%
Sector median 191.7%
Sector lowhighTop 37% in sector
How much of revenue becomes profit?
-673.2%
Sector median -2.4%
Sector lowhighBottom 7.2% in sector
How much did it earn on its own capital?
-62.3%
Sector median -4.5%
Sector lowhighBottom 13.6% in sector

Source filing: annual report (consolidated) — view original

3

Price attractiveness

27.1/100
Is the price expensive relative to earnings?
Loss-making (P/E not computable)
Sector median P/E of profitable peers 16.3x · 58% loss-making
Sector lowhighBottom 8.7% in sector
Is the price expensive relative to book value?
1.85x
Sector median 1.61x
Sector lowhighBottom 45.5% in sector

Valuation uses the Sep 1, 2026 close and market cap

4

Shareholder Return

Single-indicator axis37.5/100
Does the company actually pay dividends?
0.0%
Sector median 0.0%
Sector lowhighBottom 37.5% in sector

Source filing: annual report (consolidated) — view original

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 2, 2026

Of 9 items: 1 met · 2 not met · 6 not computable

Not metMetNot computable

Positive net income
Whether net income (attributable to owners where available) is above zero.
Not met
-₩15.4B
Positive operating cash flow
Whether cash flow from operations is above zero.
Not met
-₩14B
Return on assets up
Whether net income over beginning total assets rose from the prior year.
Not computable

Not computed — required financial data is unavailable

Operating cash flow exceeds net income
Whether operating cash flow is greater than net income.
Met
-₩14B vs -₩15.4B
Liabilities-to-assets ratio down
Whether total liabilities as a share of total assets fell from the prior year.
Not computable

Not computed — required financial data is unavailable

Current ratio up
Whether current assets over current liabilities rose from the prior year.
Not computable

Not computed — required financial data is unavailable

Shares outstanding not increased
Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.
Not computable

Not computed — share count data is unavailable

Operating margin up
Whether operating income over revenue rose from the prior year.
Not computable

Not computed — required financial data is unavailable

Asset turnover up
Whether revenue over beginning total assets rose from the prior year.
Not computable

Not computed — required financial data is unavailable

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (consolidated) — view original

Grade change history

Jul 23, 2026D

Methodology version change (v2.0 applied)

Jul 15, 2026DVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Disclosure & financial badges

Factual records determined from public filings and periodic reports by fixed rules — not buy/sell signals.

Negative-evidence group (dilution, loss, dispute)Mixed interpretationPositive-evidence group (shareholder return)Dots classify the disclosure type by the direction of research evidence — not an assessment or investment judgment about this company.

Disclosure event history

CB with conversion-price adjustment clause (past 36 months)

1 convertible bond (CB) issuance resolutions including a downward conversion-price adjustment (refixing) clause were disclosed in the past 36 months (latest filing 2026-04-29). View filing

Determined as of 2026-09-02

Recent filings for this stock

Last 120 days · monitored filing types only
Periodic report filedAug 14, 2026Source
Periodic report filedMay 15, 2026Source

View in the filings calendar →